Talaris Therapeutics (TALS) director Ildstad sold 6,551 shares for $13.4K at an average $2.05
Insider transactions reported
Suzanne Ildstad (director at Talaris Therapeutics Inc., TALS) reported that they sold 6,551 shares for $13.4K at an average $2.05 between Feb 16, 2023 and Feb 17, 2023. After these transactions the filing shows 3,074,895 shares held directly.
- Reporting person
- Ildstad Suzanne
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Feb 16, 2023 | Open-market sale (S) | Common Stock1 | -2,939 | $2.06 | $6,040 | 3,078,507 direct |
| Feb 17, 2023 | Open-market sale (S) | Common Stock2 | -3,612 | $2.05 | $7,406 | 3,074,895 direct |
Holdings before and after
- Common Stock: 3,081,446 to 3,074,895 direct
Other positions listed
- Common Stock: 1,200,000 indirect, by GRAT
- Common Stock: 654,205 indirect, See footnote
- Common Stock: 654,205 indirect, See footnote
Footnotes from the filing
- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.05 to $2.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. These shares are held in a trust for the benefit of the Reporting Person's son. The Reporting Person's son is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- 4. These shares are held in a trust for the benefit of the Reporting Person's daughter. The Reporting Person's daughter is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
FAQ
What did Ildstad report in this TALS Form 4?
Suzanne Ildstad (director at Talaris Therapeutics Inc., TALS) reported that they sold 6,551 shares for $13.4K at an average $2.05 between Feb 16, 2023 and Feb 17, 2023. After these transactions the filing shows 3,074,895 shares held directly.
How many TALS shares does Ildstad hold after this filing?
The filing shows 3,074,895 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this TALS insider sale made under a 10b5-1 plan?
The filing's footnotes do not mention a Rule 10b5-1 trading plan.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for TALS
Earlier insider filings at TALS
- Feb 3, 2023SEC Form 4 filed by Zdanowski Michael
- Feb 3, 2023SEC Form 4: Requadt Scott was granted 4 shares, increasing direct ownership by 0.00% to 590,193 units
- Feb 3, 2023SEC Form 4 filed by Krieger Nancy
- Feb 3, 2023SEC Form 4 filed by Fenton Mary Kay
- Sep 13, 2022SEC Form 4: Zdanowski Michael was granted 120,000 shares, increasing direct ownership by 8,163% to 121,470 units
Keep researching TALS
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Follow TALS and get a push notification the moment its next story breaks.